Geron is a biopharmaceutical company that is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. Imetelstat has been granted both Fast Track and orphan drug designations by the U.S. Food and Drug Administration, for the treatment of patients with transfusion-dependent anemia due to lower risk myelodysplastic syndromes, who do not have a deletion 5q chromosomal abnormality and who are refractory or resistant to treatment with an erythropoiesis stimulating agent, and for the treatment of patients with relapsed/refractory myelofibrosis. Co. has global rights to imetelstat, which was discovered and developed at Co. The GERN stock yearly return is shown above.
The yearly return on the GERN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GERN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|